Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
April 30, 2024
Assignee:
Bristol-Myers Squibb Company
Inventors:
Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
Abstract: Embodiments of the present disclosure relate to materials and methods for preparing a clathrate-forming composition comprising a plurality of linear glucomonomer chains of about 15 to about 100 D-glucopyranosyl residues linked by ?-1,4 linkages, wherein the linear glucomonomer chains are a product of partial amylolysis of a modified starch substrate and wherein the product is flowable at temperatures within a range of 4-20° C. at about 20% w/v solids content. The present disclosure further describes methods of using the clathrate-forming compositions to form molecular dispersions or clathrates with hydrophobic guest molecules, kits for use in these methods, and molecular dispersions or clathrates obtained from the materials.
Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.
Abstract: It is provided i) an amorphous carbohydrate with improved chemical stability and/or physical features, ii) a method for producing an amorphous carbohydrate with improved chemical stability and/or physical features, and iii) a method for improving the chemical stability and/or the physical features of an amorphous carbohydrate.
Type:
Grant
Filed:
November 21, 2022
Date of Patent:
March 26, 2024
Assignee:
GLYCOM A/S
Inventors:
Benjámin Podányi, Pierre Chassagne, Martin Matwiejuk, Markus Jondelius Hederos
Abstract: Provided are a method of treating chronic kidney disease or one or more symptoms thereof, or reducing a complication related to chronic kidney disease, the method comprising, administering a therapeutically effective amount of gamma-cyclodextrin oligomer to a subject in need thereof. The gamma-cyclodextrin oligomers are effective in cholesterol metabolism enhancement, cholesterol efflux, reducing inflammatory cytokine secretion, renal clearance of cholesterol and/or reducing albuminuria. Therefore, the gamma-cyclodextrin oligomers can be used to treat or alleviate chronic kidney disease, symptoms thereof and/or a complication related to chronic kidney disease.
Abstract: Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.
Type:
Grant
Filed:
February 11, 2022
Date of Patent:
March 5, 2024
Assignee:
Tulavi Therapeutics, Inc.
Inventors:
Corinne Bright, Kondapavulur T. Venkateswara-Rao, Emily Stein
Abstract: Described herein are methods for treating inflammation, swelling and secondary damage of the vascular and lymphatic system in a subject, for example of the brain, spinal cord, and lungs; from organ reperfusion, e.g., resulting from endothelial leakage, glycocalyx dysfunction or loss of structural integrity of the glycocalyx.
Abstract: Provided herein are polymer-drug conjugates with enhanced antibacterial efficacy. These conjugates include a polymer comprising a plurality of masked cationic functional groups and an antibiotic drug linked to the cationic polymer by a pH-sensitive linker. The masked cationic functional groups may be converted in aqueous solution to free cationic functional groups faster at a pH below 7 than a pH above 7. The cationic functional groups may be masked as either an uncharged functional group or by an ion pair with a neighboring anionic functional group attached to the polymer. The pH-sensitive linker releases the drug faster in aqueous solution at or below a pre-determined pH value selected from a range of 4.5 to 7 than a pH value above 7.
Abstract: Composition and methods for treating infectious and inflammatory diseases using saccharide based products and therapies. Products can be implemented as a nutritional supplement, a food, a feed, a food additive, a feed additive, a therapeutic product, a rehydration salt, or a rehydration solution. The present disclosure relates generally to the fields of compositions and products containing the compositions, and the use of the compositions or the products for preventing and/or treating infectious or inflammatory diseases or conditions in particular gastrointestinal and respiratory diseases (diarrhea and influenza infections) or inflammatory.
Abstract: A method for treating sleep disturbance according to an embodiment of the present disclosure includes administering to a subject in need thereof a composition including saponarin of Chemical Formula 1, a salt thereof acceptable for use in food, or a hydrate thereof as an effective component: In an animal model with lack of sleep caused by caffeine, saponarin of the present invention restores the travel distance, mobility time, mobility frequency, and immobility time to normal as well as increases the mRNA expression of neuropeptide Y, cholecystokinin, and GABA A ?1 receptor, thereby alleviating sleep disturbance. Therefore, the saponarin of the present invention can be advantageously used as a raw material for a functional health food or a pharmaceutical product for preventing, alleviating, or treating sleep disturbance.
Type:
Grant
Filed:
September 26, 2019
Date of Patent:
February 20, 2024
Assignee:
KOREA INSTITUTE OF ORIENTAL MEDICINE
Inventors:
Mi Young Lee, Yu Ri Kim, Young Hwa Kim, Bo-Kyung Park
Abstract: Embodiments of the present application relate to the preparation of 2?-O-protected nucleoside phosphoramidites and conjugation of the 2?-O-protected nucleoside to a solid support. More specifically, the present application relates to nucleosides having a hydroxy protecting group at the 2? position that reduces migration to the 3? position during RNA (e.g., mRNA) synthesis and can be readily removed under mild conditions without the use of toxic metal-containing reagents. Methods of using the nucleosides described herein in RNA synthesis are also disclosed.
Type:
Grant
Filed:
November 28, 2022
Date of Patent:
February 13, 2024
Assignee:
Hongene Biotech Corporation
Inventors:
Wing C. Poon, Ruiming Zou, Aldrich N. K. Lau, David Yu, Gengyu Du, Yun-Chiao Yao, Gang Zhao
Abstract: The present invention relates to a synthetic oligosaccharide of general formula (I): T*-[(—Ux+4—Ux+3—Ux+2—Ux+1—Ux)m—(Vx+2—Vx+1—Vx)1-m-T-O-L-E that is related to Klebsiella pneumoniae serotype O3, O3b and/or O5 lipopolysaccharide and conjugate thereof. Said synthetic oligosaccharide, said conjugate and pharmaceutical composition containing said synthetic oligosaccharide or said conjugate are useful for prevention and/or treatment of diseases associated with Klebsiella pneumoniae. Furthermore, the synthetic oligosaccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against Klebsiella pneumoniae serotype O3, O3b and/or O5 bacteria.
Type:
Grant
Filed:
November 30, 2018
Date of Patent:
February 6, 2024
Assignee:
IDORSIA PHARMACEUTICALS LTD
Inventors:
Arun Naini, Daniel Knopp, Bopanna Monnanda, Arne Von Bonin, Claney Lebev Pereira
Abstract: A compound having Formula (I) or Formula (II): or a mixture thereof, in which R is —H; —CH3; —CH—(CH3)2; —CH2—CH—(CH3)2; —CH—(CH3)—CH2—CH3; —CH2—(C6H5); —CH2—(3-indole); —CH2—CH2—S—CH3; —CH2—OH; —CH—(CH3)—OH; —CH2—SH; —CH2-(p-C6H4OH); —CH2—CH2—CH2—CH2—NH2; —CH2—CO—NH2; —CH2—CH2—CO—NH2; —CH2—CH2—COOH; —CH2—COOH; or —CH2—CH2—NH—C?NH2(NH2); and X is a suitable non-interfering anion, a process for making the compound having Formula (I) or Formula (II), and a process for reacting the compound having Formula (I) or Formula (II) or a mixture thereof with a (poly)saccharide to form a cationized (poly)saccharide.
Abstract: The present invention relates to a method for producing an alginic acid-folic acid conjugate, an alginic acid-folic acid conjugate produced thereby, and a pharmaceutical composition containing the same. According to the method of producing an alginic acid-folic acid conjugate using a carboxy-protecting group and a leaving group, the hydroxyl group of alginic acid forms an ester group with the carboxyl group of folic acid. Thus, the alginic acid-folic acid conjugate may clearly distinguish cancer cells from normal tissue by more effectively targeting cancer cells than a conventional alginic acid-conjugated folic acid in which the amine group of folic acid is covalently bonded to the carboxyl group of alginic acid. Accordingly, the alginic acid-folic acid conjugate may be effectively used for precise diagnosis and efficient surgical resection of cancer lesions.
Type:
Grant
Filed:
February 1, 2022
Date of Patent:
January 30, 2024
Assignee:
SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Abstract: Disclosed herein is method for conjugating a metal chelating agent to a functionalized dextran by reacting a chelator with an aminated dextran backbone, where the chelator comprises a one, and only one, derivatized carboxylic acid group to form a chelator-dextran complex. In certain aspects, the dextran-chelator complex is substantially free of intra- or intermolecular crosslinking. In certain aspects, the functionalized dextran is an amine dextran, an alkynyl dextran, or a thiol dextran. In exemplary implementations, the functionalized dextran is an amine dextran. In further embodiments, one and only one carboxylic acid group on the chelating agent is derivatized as a N-hydroxysuccinimide (NHS) ester.
Abstract: The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more cardiac diseases in feline animals.
Abstract: The present invention is directed to the discovery that AMPK activation through Galectin 9 induces autophagy and affects other related processes in response to lyosomal damage which occurs and the use of that mechanism in the treatment of autophagy disease states and/or conditions. The use of modulators of AMPK and optionally a modulator of Galectin 9, TAK1 and/or a lysosomotropic agent for the treatment of autophagy-mediated disease states and/or conditions is described as are pharmaceutical compositions.
Type:
Grant
Filed:
December 29, 2020
Date of Patent:
November 21, 2023
Assignee:
UNM RAINFOREST INNOVATIONS
Inventors:
Vojo P. Deretic, Jia Cassano, Bhawana Bissa
Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.
Abstract: Methods of treating trypanosomiasis and, particularly, methods of treating trypanosomiasis using neohesperidin dihydrochalcone. Such methods of treatment are useful in, for example, animals selected from the group consisting of cattle, sheep, pigs, goats, horses, and camels.